TS Harigopal

Mr. Harigopal joined us in 2021 and serves as our Senior Vice President of Group Operations overseeing the Information Technology, Facilities and Procurement functions. Mr. Harigopal has over 25 years of experience in the life sciences industry. Prior to joining us, Mr. Harigopal was Director of Information Technology at Cytokinetics, a public, clinical-stage biotechnology company. Prior to Cytokinetics, he held IT roles in various capacities in Pharmacyclics (acquired by Abbvie) and Johnson & Johnson. Mr. Harigopal received his BA in Finance and Information Technology from the University of Bombay, and an MBA with specialization in Finance and Global Supply Chain from the California State University, East Bay.

Eric W. Humke, M.D., Ph.D.

Dr. Humke joined IGM in 2019 and currently serves as our Senior Vice President of Clinical Research and Development. Prior to joining us, Dr. Humke was Senior Medical Director at Genentech where he led numerous clinical programs from research through Phase 2 trials in Research & Early Clinical Development. These programs evaluated several antibody drug conjugates for multiple myeloma, lung, pancreatic, ovarian, and endometrial cancer and various small molecule inhibitors for multiple myeloma, lung and breast cancer. Prior to joining Genentech, he was an Instructor of Medicine in the Division of Oncology at the Stanford University School of Medicine where he conducted basic science research and cared for patients in the oncology clinic. Dr. Humke received a B.S. in Neuroscience from Brown University and an M.D., Ph.D. from the University of Michigan. Dr. Humke completed his internal medicine residency at Washington University in St. Louis (Barnes-Jewish Hospital) and a medical oncology fellowship at Stanford University.

Kim Michelson

Ms. Michelson has served as Senior Vice President of Developmental Operations since May 2023. Prior to joining IGM, she served as Senior Vice President of Clinical Operations at Medpace, a global drug, biologic and medical device clinical research organization. Ms. Michelson has also held numerous global leadership roles in clinical trial management and operations at Medtronic, Abraxis Bioscience, PPD and Amgen. Her early operations and drug development experience were formed at Quintiles and Ionis Pharmaceuticals (formerly Isis Pharmaceuticals) where she developed her safety and clinical trial management interests. Ms. Michelson started off her career in oncology and critical care nursing. She holds a B.S. in Nursing from the Johns Hopkins University School of Nursing.

Marvin S. Peterson, Ph.D.

Dr. Peterson joined us in 2017 and serves as our Executive Vice President of Process Sciences and Manufacturing. Dr. Peterson also served as Senior Director, Manufacturing at MabVax Therapeutics, a biotechnology company, from 2015 to 2017 and as Senior Director, Upstream Process Development and Manufacturing at Ambrx, a biotechnology company, from 2014 to 2015. Dr. Peterson has also served in manufacturing, scientific and leadership positions at Bristol-Myers Squibb, Eli Lilly, Celgene and Shire. Dr. Peterson received a B.S. in Chemical Engineering from the University of Colorado, Boulder and a Ph.D. in Chemical Engineering from Purdue University. He also completed a post doctorate at the University of Minnesota, BioProcess Technology Institute. 

Elaine Sapinoso

Ms. Sapinoso has served as our Senior Vice President of Quality since 2023. Prior to joining IGM, Ms. Sapinoso was previously Senior Vice President of Global Quality at Abzena and Vice President of Quality and Regulatory Affairs at Aji BioPharma. Ms. Sapinoso has served in senior Quality leadership roles at global drug development and manufacturing organizations supporting biologics drug substance and drug product operations, and provided leadership across Quality functions including Quality Assurance, Quality Control, and Validation. Ms. Sapinoso has also developed phase appropriate quality systems within manufacturing organizations to advance them from clinical development to commercial approval. In her 26 years in Quality, she has led manufacturing facilities through successful regulatory site inspections resulting in eleven commercial facility and product approvals. Ms. Sapinoso received a B.S. in Biology from De La Salle University, and an M.B.A. from the University of California, Los Angeles with a specialization in Corporate Governance.

Faraz Siddiqui

Mr. Siddiqui joined us in 2023 and serves as our Senior Vice President, Manufacturing Operations. Mr. Siddiqui has over 25 years of experience in the biotech/pharmaceutical industry with extensive expertise in manufacturing strategy and operations, CMC development and cross-functional leadership. He joins us most recently from Instil Bio where he was the Vice President, Process Development and Manufacturing operations in the US and UK for a TIL therapy targeting multiple solid tumors. He established and led the global process development and manufacturing operations which included CMC strategy, development, transfers and filings to multiple Health Authorities. He also spent 3 years at Kite Pharma as Senior Director of Technology Excellence within Process Development, where he was responsible for technology transfers, technology development and process development business operations. Prior to that, he spent 19 years at Roche/Genentech in various roles of increasing responsibilities in internal and external manufacturing as well as leading global biologics technology transfers across the Roche network. Mr. Siddiqui has a B.S. in Biochemistry from UC Davis and an M.B.A from St. Mary’s College of California.

Angus M. Sinclair, Ph.D.

Dr. Sinclair joined us in 2018 and serves as our Senior Vice President of Immuno-oncology. Prior to joining IGM, Dr. Sinclair served as Senior Director, Oncology Research at Northern Biologics, a biotechnology company, from 2015 to 2018. He also previously served in various scientific and leadership positions at Amgen, including most recently as Scientific Director, Oncology Research, from 2011 to 2015. Dr. Sinclair received a B.Sc. in Molecular Biology from the University of Edinburgh and a Ph.D. in Hematology/Molecular Biology from the National Institute for Medical Research/University College London.

Steven Weber

Mr. Weber joined us in 2022 and serves as our Senior Vice President, Corporate Controller and Principal Accounting Officer. Prior to joining IGM, Mr. Weber served as Vice President and Principal Accounting Officer at Aeglea Biotherapeutics, a public, clinical-stage biotechnology company. Prior to Aeglea, he held controller and finance leadership roles at SACHEM, American Campus Communities and Citco Fund Services. Mr. Weber began his career as a public accountant at PricewaterhouseCoopers and is a certified public accountant in the state of Texas. He received a B.B.A. in Accounting and an M.P.A. from the McCombs School of Business at the University of Texas at Austin.

Felix J. Baker, Ph.D.

Dr. Baker has served as a member of our board of directors since January 2021. Dr. Baker is a Managing Member of Baker Bros. Advisors LP (“BBA”), a biotechnology-focused investment adviser to fund partnerships whose investors are primarily endowments and foundations. Dr. Baker founded BBA, together with his brother Julian Baker, in 2000. Dr. Baker has served on the boards of biotechnology and pharmaceutical companies, including Seagen since July 2003, Talis Biomedical since July 2013, Kodiak Sciences since September 2015, and Kiniksa Pharmaceuticals since October 2015, and he previously served on the board of Alexion Pharmaceuticals from June 2015 to February 2021. Dr. Baker holds a B.S and a Ph.D. in Immunology from Stanford University, where he also completed two years of medical school.

M. Kathleen Behrens, Ph.D. 

Dr. Behrens has served as a member of our board of directors since January 2019. Since December 2009, Dr. Behrens has served as an independent life sciences consultant and investor. From January 2012 to June 2014, she served as the Co-Founder, President, Chief Executive Officer and director of the KEW Group, a private oncology services company. From 1996 to December 2009, Dr. Behrens served in various roles at RS Investments, an investment management and research firm, including as a General Partner for selected venture funds. Prior to this, from 1983 to 1996, she served as a General Partner and Managing Director at Robertson Stephens & Co. Since March 2009, Dr. Behrens has served as a member of the board of directors of Sarepta Therapeutics, a medical research and drug development company, and as Chairwoman since April 2015, as well as Chair of its audit committee and a member of its research and development committee. She has served as Chairwoman of the board of directors of MiMedx Group, a biomedical company, since June 2019, and as a member of its nominating and governance committee and audit committee. Dr. Behrens served on the board of directors of Amylin Pharmaceuticals, a biopharmaceutical company, from June 2009 until its sale to Bristol-Myers Squibb in 2012. She previously served as a member of the President’s Council of Advisors on Science and Technology (PCAST) from 2001 to early 2009 and as Chairwoman of its subcommittee on Personalized Medicine. She has also spent time as a public-market biotechnology securities analyst and a venture capitalist focusing on healthcare, technology and related investments. She also previously served on the Board on Science, Technology and Economic Policy for the National Research Council and as a Director, President and Chairwoman of the National Venture Capital Association. Dr. Behrens received a B.S. in Biological Sciences and a Ph.D. in Microbiology from the University of California, Davis.